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Therapeutic approaches in pediatric pulmonary arterial hypertension (PAH) are based pri-
marily on clinician experience, in contrast to the evidence-based approach in adults with
pulmonary hypertension. There is a clear and present need for non-invasive and objec-
tive biomarkers to guide the accurate diagnosis, treatment, and prognosis of this disease
in children. The multifaceted spectrum of disease, clinical presentation, and association
with other diseases makes this a formidable challenge. However, as more progress is
being made in the understanding and management of adult PAH, the potential to apply
this knowledge to children has never been greater. This review explores the state of the
art with regard to non-invasive biomarkers in PAH, with an eye toward those adult PAH
biomarkers potentially suitable for application in pediatric PAH.
Keywords: pulmonary arterial hypertension, pediatric, biomarkers, imaging, magnetic resonance, echocardiogra-
phy, right ventricle
INTRODUCTION
Our understanding of pulmonary hypertension (PH) in chil-
dren has been hampered over the years by a number of factors.
Despite the important benefits of off-label application to children
of PH therapies originally developed for adults, the disease remains
lethal. The study of PH in children is further complicated by addi-
tional factors such as the complexity of accurate diagnosis, the
multifactorial nature of the disease, and a relatively poor under-
standing of the natural history of the disease. The need for earlier
detection, more accurate and sensitive biomarkers of disease and
disease progression, and a personalized approach to therapy can-
not be overstated. To date, biomarker reviews for PH have focused
on adults. This review focuses on the unrealized promise of bio-
markers in pediatric PH, their potential to improve our ability to
Abbreviations: CEC, circulating endothelial cell; CHD, congenital heart disease;
CT, computed tomography; EC, endothelial cell; Echo, echocardiography; EPC,
endothelial progenitor cell; MRI, magnetic resonance imaging; PAH, pulmonary
arterial hypertension; PET, positron emission tomography; PH, pulmonary hyper-
tension; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV,
right ventricle; SPECT, single photon emission computed tomography; TDI, tissue
Doppler imaging.
treat PH, and the capacity for adult biomarkers of PH to be applied
to children.
DEFINITION AND CLASSIFICATION OF PEDIATRIC
PULMONARY HYPERTENSION
Pulmonary hypertension is a condition characterized by increased
blood pressure and resistance in the arterial vasculature of the lung
as the result of numerous pathological mechanisms, eventually
culminating in right ventricular failure. The development of the
disease may be linked to other diseases as a derived secondary
disease, or may develop solitarily with known etiology, or may
be idiopathic (1). PH may develop in both children and adults,
regardless of age. Currently, as elaborated by the World Health
Organization Dana Point 2008 Clinical Classification system, there
are five categories of PH, with the most common form of child-
hood PH (amounting to ~90% of cases) occurring in Group I
(1). Group I, denoted as pulmonary arterial hypertension (PAH),
includes idiopathic (IPAH), familial (FPAH), PAH associated with
venous and/or capillary disorders, or associated with other diseases
(APAH), including HIV infection, drugs, toxins, congenital shunts
between pulmonary and systemic circulation, collagen vascular
disease, and others. Groups II–V are categorized as PH associated
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left heart disease, PH associated with lung diseases/hypoxia, PH
due to embolic and/or chronic thrombotic disease, and PH
associated with miscellaneous conditions, respectively.
Current standards define PAH in adults and children in a similar
way, with specified parameters of a mean pulmonary artery pres-
sure ≥25 mmHg, a normal capillary wedge pressure ≤15 mmHg,
and an increased pulmonary vascular resistance (PVR) (2). The
minimum value for increased PVR remains controversial, espe-
cially in pediatric patients, where PAH caused by left-to-right
congenital shunts is common, and in such cases no significant
increase in PVR is observed (3). Therefore, most experts suggest
a PVRI ≥3 WUm2 for diagnosis of pediatric PAH (3). When left
untreated, children with PAH are predicted to have lower survival
rates and poorer prognosis than adults (4). Abnormal lung and
cardiac development is known to play a factor in pediatric PAH, in
which left-to-right shunts due to congenital heart defects causes
increased flow in the pulmonary vasculature, known as the Eisen-
menger syndrome (5). Studies have shown the pathophysiology
for PAH to be comparable between children and adults (6–8), yet
there remains limited data on the efficacy of current adult thera-
pies extrapolated to children. Pediatric PAH is a rare, multifactorial
disease, with no current cure. Therefore, there is a need to stan-
dardize prognostic procedures for the establishment of early and
appropriate therapeutic responses.
Clinically, children with PAH show various symptoms, may
be non-specific, and are dependent upon age. Symptoms include
shortness of breath, exercise fatigue, respiratory symptoms and
chest pain (9). Current diagnostic methods include echocardiog-
raphy (Echo), exercise testing, right heart catheterization (RHC),
and vasodilator testing for both adults and children (10). In chil-
dren in whom RHC is deemed unsuitable, the diagnosis is usually
reached as a validated consensus from a team of pediatric PH spe-
cialists. And subsequent therapy is based on similar algorithms
used in adults as well as the experience of the clinical team (11).
EPIDEMIOLOGY ANDWORLDWIDE HEALTH BURDEN OF PH
For adults with PAH, studies have reported an incidence of 7.6
per million cases of adults per year and a prevalence of 52 cases
per million (12). Limited data are available on disease registries
of pediatric PAH, due to small patient numbers, and because ear-
lier registries lack standardized assessments (4). However, recently,
a number of studies have been completed for disease registry
and to further improve understanding of the disease epidemi-
ology in children (13). PAH in children is rarer than in adults.
Data from a registry in the Netherlands reported the incidence
of pediatric PAH to be 63.7 cases per million children, with a
majority of those cases being PAH diagnosed (57.9 cases per
million children) (14), a comparable incidence to that seen in
adults. In a study conducted by the UK Pulmonary Hypertension
Service for Children, survival rates for PAH diagnosed children,
treated with modern therapies (mono- or combination thera-
pies, or disease-specific therapy, including treatment with calcium
channel blockers, bosentan, and intravenous epoprostenol), were
reported at ~90.5, 82.8, and 64.2%, at 1, 3, and 5 years, respectively
(15). Another study conducted by the Registry to Evaluate Early
and Long-Term PAH Disease Management (REVEAL) reported
survival rates of IPAH/FPAH and APAH-CHD children, treated
with etiologic specific therapies, at 96, 84, and 74% for 1, 3, and
5 years, respectively (16). These data are supported by results in
similar studies (14, 17, 18). Data show varying survival estimate
differences between IPAH and APAH patients (14–16), which may
be due to limited sample sizes and various subgrouping analy-
sis. Compared to adults, data from the Tracking Outcomes of
Pediatric Pulmonary Hypertension (TOPP) showed a higher dis-
tribution of APAH associated with CHD in children, with a very
low occurrence of PAH associated with tissue diseases, HIV, drugs,
and portopulmonary hypertension (19). A higher occurrence of
the disease in children has been observed in females than males at
a 2:1 ratio (20), which is lower compared to the 4:1 ratio seen in
adult patients (21).
The recent data from these registries report preliminary find-
ings on the efficacy of adult therapies in children, with positive
improvements in the prognosis. Though adults and children with
PAH have shown similar pathobiology and clinical responses to
treatment therapy, much is still unknown about pediatric PAH,
and full elucidation of the differences between adults and children
still remains.
BIOMARKER DEFINITION
The National Institutes of Health defines a biomarker as:“a charac-
teristic that is objectively measured and evaluated as an indicator
of normal biologic processes, pathogenic processes, or pharma-
cologic responses to therapeutic intervention” (22). This broad
definition is particularly apt for pediatric diseases, which may
involve developmental disturbances with and without pathogenic
and pharmacologic processes. Recently, several excellent reviews
on biomarkers in adult PAH have been published (23–25). This
review focuses on those biomarkers that have been proposed for,
or may have specific relevance to, pediatric PAH.
GENERAL BIOCHEMICAL CLASSES OF PULMONARY
HYPERTENSION BIOMARKERS
The ultimate biomarker for any disease would be one that involves
a procedure that is easy to perform, painless, inexpensive, while
offering high specificity, and low rates of false negatives and pos-
itives. For a biomarker to be effective in a pediatric population,
additional factors such as patient compliance must be considered.
During the typical patient workup, many routine tests are ordered
that can serve as biomarkers. Some sources, such as plasma, could
potentially be screened to simultaneously measure panels of bio-
markers. Indeed, there is unlikely to be any single biomarker for
PAH that perfectly satisfies all of these requirements. Furthermore,
in the age of “personalized medicine,” biomarkers may be of bet-
ter value when measured and compared longitudinally in a single
patient, rather than compared to others as absolute values at single
time points. As a starting point, PAH is a hemodynamic definition,
representing a spectrum of diseases that ultimately leads to right
heart failure. Therefore, biomarkers for PAH should correlate in
some fashion to a hemodynamic measurement such as PA pressure,
PA wedge pressure, PVR, etc., and/or to a clinical measurement
such as survival, pulmonary function test, etc. (Figure 1) (23).
The pathobiology of PAH is multifactorial and complex. There-
fore, it should not be surprising that potential biomarkers likely
should reflect aspects of the underlying disease process (Figure 1).
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FIGURE 1 | Pulmonary arterial hypertension (PAH) is a syndrome that is
idiopathic in origin or arises in association with a large number of
disease processes. Biomarkers for PAH should correlate in some fashion to a
hemodynamic measurement such as PA pressure, PA wedge pressure,
pulmonary vascular resistance, etc., and/or to a clinical measurement such as
survival, pulmonary function test, etc. Since the pathobiology of PAH is
multifactorial and complex, it should not be surprising that potential
biomarkers will likely reflect aspects of the underlying disease process.
Damage to pulmonary endothelium and ongoing endothelial cell
(EC) dysfunction is thought to play a fundamental role in the
pathogenesis of PAH (26). Many of the therapies used in patients
with PH relate to the biology of dysfunctional endothelium by tar-
geting prostaglandins, nitric oxide, and endothelins (23). Inflam-
mation in the lungs and right ventricle is thought to play significant
roles in the pathobiology of PAH (27, 28). Mast cells, monocytes,
macrophages, T cells, and B cells have all been shown to partici-
pate at some level in PAH (29). Both innate and acquired immune
cells are rich sources of cytokines and chemokines that have been
reported to be prognostic biomarker in adult PAH (23). The larger
question of whether these inflammatory markers are indicators
of general inflammation and oxidative stress or whether they are
specific for pulmonary vascular disease and/or right ventricle dys-
function is not known. In addition, significant variability in the
levels of some cytokines (ex: IL-6) has been reported (30, 31),
likely due to differences in patient cohorts and in assay method-
ology. These reproducibility issues must be resolved before their
widespread acceptance and use in the clinic. Finally, biomark-
ers of heart dysfunction have been increasingly used to evaluate
and often prognosticate PAH. This is evidenced by a PubMed
search conducted in January 2014 using the terms “biomarkers
right ventricle pulmonary hypertension,” which resulted in 90 hits
with 52/90 published in the last 5 years [four excellent examples
(32–35)]. Measurement of atria natriuretic peptide (ANP) and
most especially B-type natriuretic peptide (BNP) and N-terminal
(NT)-proBNP provide important and reproducible prognostic
markers with regard to cardiac function vis-à-vis blood volume
and pressure (36).
SPECIFIC CLASSES OF PULMONARY HYPERTENSION
BIOMARKERS
For the purposes of this review, we exclude invasive hemodynam-
ics but include as a biomarker, any modality that yields data that
can aid in assessment of PAH at any point in its course. Such a
perspective admittedly ignores real-world limitations of resources,
expertise, and the recruitment of sufficiently large enough patient
cohorts. Specific classes of biomarkers for PAH can be orga-
nized into those arising from imaging tests, circulating biomarkers,
exhaled breath, and urinary biomarkers.
IMAGING TESTS
Echocardiography
The gold standard for assessment of PAH is RHC, in which mean
pulmonary artery pressure (pa), cardiac output, and PVR mea-
surements can be obtained (37). Three recent reviews provide
excellent summaries of RHC (38–40). Prior to invasive hemo-
dynamics, an echocardiogram is almost always performed. Echo
is an important screening tool for the diagnosis of PAH, and is
also the standard of care for non-invasive monitoring of PH pro-
gression. Echocardiographic findings, although subject to signifi-
cant operator variability (41), reliably provide several estimates of
hemodynamic function that closely correlate with measurements
obtained by RHC. A large variety of estimates of RV function can
be made, depending on assumptions of RV geometry. Flattening
and inversion of the inter-ventricular septum toward the left ven-
tricle is highly suggestive of PAH (42). Detailed echocardiographic
methodology and the equations used for calculation of variables
are detailed elsewhere (43). Recently, the importance of Doppler
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Echo based measurement of the acceleration time of pulmonary
flow has become an important metric, as has the tricuspid annular
plane systolic excursion (TAPSE) (44). Decreased TAPSE has been
associated with poor prognosis in patients with dilated cardiomy-
opathy, and may have correlation with pa and PVR (45). Recently,
tissue Doppler imaging (TDI) has been used to predict adverse
outcome in children with IPAH (46). This approach measures
three waveforms that represent the cardiac cycle: systolic myocar-
dial velocity (Sm), early diastolic myocardial relaxation velocity
(Em), and late diastolic myocardial velocity associated with atrial
contraction (Am). This prospective study compared 51 children
with IPAH to 51 controls and found that tricuspid Em had higher
correlation with plasma BNP levels and hemodynamics than tri-
cuspid Sm. These findings differed with those from adults (47–49),
but, importantly, support our thesis that biomarkers in adults
with PH should be systematically and comparatively examined
in children with PAH. As with nearly all studies of pediatric PAH,
interpretation of the study is constrained by the relatively small
sample size. In addition, the patients were placed on vasodilators
suited to their particular clinical portraits and all survived, and so
the ability of TDI to predict mortality was not assessed. Neverthe-
less, this prospective study illustrates the power of non-invasive
testing by Echo as part of the biomarker toolkit of the pediatric
cardiologist.
Computed tomography
Multi-detector computed tomography (CT) is used routinely
to assess both cardiovascular and lung parenchymal changes in
patients with PAH. With the advent of respiration-timed CT gat-
ing with electrocardiography, the technique has vastly improved
(50). As much as its value has improved, correlation with measure-
ments such as main pulmonary artery diameter to pa is variable
(51–53). However, several studies have used CT imaging to estab-
lish the differential diagnosis of PAH by ruling in or out associated
pathologies such as pulmonary thromboembolism or pulmonary
fibrosis. Recent work has begun to demonstrate good correlation
between functional parameters such as right pulmonary artery
wall distensibility and diagnosis of PAH (54). As respiration gat-
ing improves along with increasing image detail, CT will continue
to be an important assessment tool for the diagnosis of PH. By
far the largest drawback to the use of CT is exposure to X rays.
Not only does this limit the capacity for CT to provide longitudi-
nal study data, its use in children is problematic and the benefits
must be weighed against exposure time. For example, the contrast
agents used are associated with kidney injury (55). Furthermore,
patient compliance (inability to hold still, claustrophobia, etc.) in
a pediatric population can be problematic.
Single photon emission computed tomography
Single photon emission computed tomography (SPECT) is a varia-
tion in CT in which gamma rays emitted from an injected radionu-
clide source are detected by a rotating gamma camera (56). The
technique allows for three-dimensional reconstruction, and when
used with specific radioligands, tissues of interest can be closely
scrutinized. Of particular interest is the ability to measure true per-
fusion with Technetium-99m labeled macro-aggregated albumin
(57). Unfortunately, acquisition of SPECT images typically takes
several minutes and breathing during acquisition affects image
resolution, yet has been performed successfully in animal mod-
els of PAH (58). As with CT, respiration gating improves image
quality. In any case, the ability to perform SPECT in pediatric
lung disease is limited, but the promise of three-dimensional
reconstructions of perfused lung vasculature is enticing.
Positron emission tomography
Positron emission tomography (PET) has seen a dramatic increase
in use over the past decade in the setting of PH. Recently, it was
shown that PAH hearts have pathologic glycolytic metabolism that
is quantitatively related to cardiac dysfunction over time (59).
Interestingly, the FDG uptake observed also seemed to corre-
late with circulating CD34+CD133+ cells (a class of biomarker
discussed in the next section). Breath-gated PET had moderate-to-
high correlation with cardiac magnetic resonance (CMR) imaging
and CT in the assessments of RV volume and ejection fraction
(60). FDG uptake by the RV reflects the severity of PVR in
PAH. Increased RV FDG uptake is a marker of poor prognosis in
IPAH and is reduced in patients receiving effective therapy (61).
What is somewhat unclear is the extent to which FDG PET in
patients with PAH truly measures increased cellular metabolism
or reflects inflammatory processes. One study recently reported
that there were no correlations between (18) FDG uptake and
hsCRP or inflammatory cytokine levels in PAH patients. However,
NT-ProBNP correlated with RV uptake in those with PH suggest-
ing that FDG PET may be a good biomarker for RV dysfunction
(62). In experimental PH, Glut1 up-regulation in proliferating vas-
cular cells in PAH accounts for increased lung FDG PET uptake.
FDG PET is sensitive to mild PAH and can monitor therapeutic
changes in the vasculature (63). Collectively, these studies strongly
suggest that metabolic imaging may be useful in therapeutic mon-
itoring of PAH patients. In adults, PET appears to be a suitable
method for assessing RV function and myocardial glucose metab-
olism in patients with PAH, as well as lung metabolic and cellular
proliferation.
For CT, SPECT, and PET, important considerations regard-
ing radiation dose vis-à-vis diagnostic benefits must be carefully
weighed. However, the value of nuclear medicine in pediatrics is
well established, as has standard dosimetry for a large variety of
radiopharmaceuticals (64).
Magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) has rapidly evolved
to be a powerful tool to measure right ventricular morphology,
and volumes and ejection fractions (65–69). The ventricular mass
index, which is the quotient of right ventricular mass over left
ventricular mass, is highly sensitive and specific for prognosticat-
ing PAH [reviewed in Ref. (70)]. Furthermore, its advantages in
spatial resolution, lower intra-operator variability, and true three-
dimensionality make it the gold standard for RV study over Echo
(71). Cardiac MRI has been successfully used to determine RV
stroke volume index, RV ejection fraction, RV mass, RV isovolumic
relaxation time, leftward ventricular septal bowing, and left ven-
tricular ejection fraction (72). With regard to children with PH,
MR can be performed safely and effectively. In one study of 26 sub-
jects, markedly abnormal RVs were found (73). One year later, no
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change in cardiac MR parameter was observed, which highlights
the advantage of MR for serial testing. Additional morpholog-
ical and functional parameters could be measured in children
to include inter-ventricular septum configuration, stress testing,
fibrosis (with late gadolinium enhancement), and pulmonary cir-
culation testing (74). A detailed treatment of the wide range of
potential uses for MRI in normal and PAH lung has been pub-
lished (75). Recently, the prognostic value of MR was evaluated
in 100 children with PAH, of which 60 were diagnosed with IPAH
(76). Almost all parameters assessed by MR correlated with clinical
metrics of disease severity and had strong correlation to invasively
measured pa. Detailed MRI assessment of heart and lung function
in children with PH at initial workup and serially in the course of
treatment will be an increasingly important tool for the clinician.
CIRCULATING BIOMARKERS
Blood is a potentially rich source of biomarkers in the setting of
pediatric PAH. Since PAH is a multifactorial and complex vascu-
lar disorder, it stands to reason that a variety of biomarkers would
be present arising from sources related to ongoing processes of
inflammation, coagulation, and ventricular strain. For this review,
we have divided blood biomarkers into compartments of cells
and non-cells (plasma or serum). Within the cellular compart-
ment, leukocytes, erythrocytes, and platelets are routinely analyzed
in the hospital laboratory setting. Recent studies have measured
microparticles, circulating endothelial cells (CECs), and endothe-
lial progenitor cells (EPCs) in peripheral and/or central blood. In
addition, a substantial number of chemokines, cytokines, and even
RNAs have been measured in the blood plasma and correlated to
physiological and clinical parameters of PAH, mostly in adults.
Cells and microparticles
Many disease states are characterized by increase or decrease in
circulating cells, often those involved in inflammation (77) or
angiogenic responses to injury/repair (78). PH, at least in adults,
is associated with EC dysfunction (79). CEC as well as EPC
are readily identifiable in adults with PAH (80, 81). Micropar-
ticles, defined as plasma membrane fragments between 0.1 and
1µm in diameter, are released during a number of physiologic
and pathophysiologic conditions by numerous cell types (82).
Recently,CECs were prospectively measured in children with IPAH
and PAH secondary to congenital heart disease, before and after
treatment (83). Importantly, rising CEC counts preceded clinical
deterioration, suggesting that CECs may be an important tool to
anticipate clinical worsening. Another study on endothelial bio-
markers reported elevated levels of circulating ECs associated with
reversible APAH-CHD in children, suggesting that endothelial
dysfunction and damage play an important role in angiogen-
esis (84). This study also included analysis of soluble markers,
and results showed that levels of angiogenic cytokine, inflamma-
tion, or endothelial microparticles were not predictors of PAH
reversibility. Additional studies by Smadja et al. showed that har-
vested endothelial colony forming cells (ECFCs) from peripheral
blood of children with IPAH and APAH-CHD had a hyperpro-
liferative phenotype with enhanced angiogenic potential when
treated with prostanoid therapy (treprostinil) in a nude preclin-
ical mouse model of limb ischemia (85). These results provide
support for the importance of EPCs in vascular repair in pediatric
PAH. On the other hand, some studies have failed to establish
any correlation between circulating EPC and pa (86). Small sam-
ple sizes, observer bias, or differences in technical approach may
explain such disparate results. Flow cytometric assessment of cir-
culating microparticles derived from platelet and erythrocytes in
young thalassemia major patients positively correlated to mark-
ers related to PH and aortic wall stiffness (87). In a small study,
microparticles form PAH patients were shown to have increased
CD39 nucleotidase activity (88). Thus, circulating vascular cells, or
microparticles derived from them, appear to be variable in num-
ber in PAH patients, may or may not correlate to clinical values,
and may be involved in the pathogenesis. Whether measured in
children or adult with PAH, a multi-center study with a large
cohort, using a standardized methodology for a specified set of
markers, should definitively establish the utility of vascular cell
measurement as a biomarker.
In addition to vascular cells, inflammatory cells can be mea-
sured in peripheral blood. Deficiencies in natural killer cells
and cytotoxic CD8+ T cells may portend risk of death in PAH
patients (89). Compared to controls, individuals with PH and
pulmonary veno-occlusive disease (PVOD) have decreased cir-
culating T lymphocytes (90). In that study, epigenetic alterations
of the granulysin gene discriminated PVOD from PAH. In yet
another study, peripheral blood mononuclear cells (PBMCs) were
purified and analyzed for expression of endoplasmic reticulum
stress and unfolded protein response markers (91). Compared
to controls, PAH patients’ PBMC had higher expression of these
markers, which in the case of the unfolded protein response effec-
tors DnaJB and BiP, correlated to inflammation (IL-6 levels) and
disease severity (pa). Importantly, these studies seem to corrobo-
rate an emerging concept of cell stress in PAH that is being borne
out in animal models of PAH (92). These results provide evidence
that analysis of circulating white blood cells by flow cytometric
quantification and subsequent gene expression characterization
represent potentially important blood tests that could be integra-
tively applied to current diagnostic and prognostic workups in
children with PAH. Indeed, elevations of subsets of monocytic
cell subsets have been identified in children with PAH (93, 94).
Such studies, if confirmed in additional cohorts, could be prospec-
tively expanded and performed serially to establish correlations to
inflammation, disease progression, and response to therapy. Dur-
ing the clinical workup, numerous opportunities are available to
measure circulating cells and microparticles, either centrally at
catheterization or peripherally.
Plasma
The plasma has been investigated in both adult and pediatric
PAH patients for a large number of biomolecules, including pro-
teins, vitamins, and nucleic acids. As with circulating cells, it is
thought that biomolecules in the plasma likely reflect underlying
disease processes of lung vascular cell dysfunction (95), ventricular
damage (96), and inflammation (97).
Plasma proteins
As mentioned above, NT-proBNP is probably the most studied
(measured) plasma protein biomarker in PAH. In children, as is
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the case with adults, NT-proBNP has prognostic value (98, 99).
The levels of NT-proBNP have been reported to be lower in chil-
dren with PH than in adults (100, 101), a finding which seems
to correspond with a decreased incidence of right heart failure
in children vs. adult patients. Similarly, cardiac troponin T is an
independent marker of mortality (102). A critically important
aspect to consider in the pediatric PAH patient is age and/or
stage of development. Indeed, children are not “small adults.”
Developmental programs driving lung vessels are thought to be
perturbed in PAH, and decreased plasma vascular endothelial
growth factor (VEGF) in infants with PAH may be a reflection of
such disturbances (103). Recent proteomic studies have demon-
strated clear feasibility in measuring plasma interleukins (ILs),
acute phase proteins, and growth factors (104, 105). Some of
these plasma proteins may simply reflect systemic inflammation
(serum amyloid A), but may also be mechanistically linked to
control of inflammatory cell phenotype (serum amyloid P). For
example, mast cells have long been implicated in the pathobiol-
ogy of PH and efforts to understand their specific contributions
have recently been re-energized (29). Growth differentiation fac-
tor (GDF)-15 (106), Endothelins (107), and C-reactive protein
(108) appear promising as biomarkers in adult PH, at least with
respect to inflammation. Recently, blood and urine leukotriene E-
4, proangiogenic factors, mast cell numbers, and mast cell tryptase
levels were higher in PAH patients, and receded subsequent to
treatment with mast cell inhibitors cromolyn and fexofenadine
(109). However, these declines were not linked to clinical improve-
ment. Nevertheless, this study provides a representative framework
to perform a comprehensive (multicompartment, multi-target)
biomarker analysis that could be applied to children with PAH.
Another study analyzing the relationship between hemodynamics
and serum levels of intracellular adhesion molecule 1 (sICAM-1)
showed that levels are elevated in children with APAH-CHD com-
pared to children with only congenital heart disease, with mean
pulmonary arterial pressure being the strongest independent pre-
dictor (110). Collectively, a large number of plasma proteins could
be systematically evaluated in children with PAH. We suggest a
multiplex platform, as we have used (104), but one in which the
protein targets have been customized to a “PH plasma proteome
signature” likely comprised of IL-6, GFF-15, sICAM-1, endothe-
lins, serum amyloid A, and serum amyloid P. High accuracy/high
precision multiplex assay platforms are already routinely capable
of measuring >84 analytes with appropriate controls on a single
96-well plate. Because of this large analytic capacity, the choice of
biomarkers to analyze might be less important as the choice to sys-
tematically adopt it. Development of close collaboration between
biotechnology industry, academia, and biopharma seems partic-
ularly suited for the task of biomarker selection, analysis, and
scope of interpretation. We offer a comprehensive recommen-
dation for specific biomarkers in the conclusion section of this
review.
Plasma non-proteins
There have been a large number of studies that have identified dif-
ferences in levels of plasma non-proteins between PAH patients,
PAH patient sub-groups, and controls [reviewed in Ref. (111)].
For this review, we have focused on vitamins and RNA species as
non-protein biomarkers, but the complete list is much longer and
beyond our scope here.
Vitamins. Vitamins are a large and diverse group of organic
compounds that are essential for normal growth and nutrition
and are required in small quantities in the diet because they can-
not be synthesized by the body. There have been a large number
of studies that have identified differences in plasma vitamin lev-
els between PAH patients, PAH patient sub-groups, and controls.
Curiously, there are very few reviews available that summarize
potential roles of vitamins in PAH. For one example, Vitamin D
levels affect the renin–angiotensin–aldosterone system, which, in
turn, affects the cardiovascular system. Low Vitamin D levels cor-
related with higher systolic PA pressure (112). As a large number of
PAH patients are therapeutically anti-coagulated, appropriate lev-
els of Vitamin K are critically important due to major bleeding risks
(113). Vitamin B12 (cobalamin C) deficiency may be associated
with, or predispose individual to, pediatric PAH (114). Vitamin
B1 (thiamine) deficiency is a cause of wet (cardiac) beriberi (115),
which often manifests with symptoms of PAH (116). Finally, Vit-
amin C deficiency (117), elevated plasma copper (118), and iron
deficiency (119) all appear to be associated with the development
of PH. In the case of iron, its measurement as a biomarker can
be extended by measurement of red cell distribution width, which
is predictive for mortality in PAH patients (120). Unfortunately,
the studies examining levels of vitamins in the setting of PAH
are sporadic and involve small numbers and/or anecdotal cases.
Furthermore, the efficacy of vitamin therapies (nutraceuticals)
in PAH is questionable. With regard to children, overall nutri-
tion is a critical component of healthy development, and can vary
widely based on a number of factors, including socioeconomic
issues. Here, we are not endorsing the therapeutic use of vitamins.
We merely suggest that measurement of vitamins could represent
powerful biomarker tools for the detection and management of
PAH, particularly in kids. It could be argued that vitamins can-
not serve as biomarkers because they simply reflect nutritional
adherence. In the strictest sense, vitamin D is not truly an essential
dietary vitamin since it can be synthesized from stored skin choles-
terol in adequate amounts by most mammals exposed to sunlight.
Similarly, vitamin A is stored as retinol or as retinyl ester, can be
converted to retinoic acid, and a role of retinoids in PH has been
investigated (121). Thus, vitamin deficiencies have been shown to
be associated with PH, in some cases precede development of PH,
and their levels in anatomical compartments do not directly reflect
nutritional adherence.
RNA. MicroRNAs (miRNAs) are non-coding single stranded
RNAs that vary in length between 19 and 25 nt. Their function
is to “fine-tune” the regulation of gene expression by affecting
mRNA stability and translation into protein (122). MicroRNAs
are implicated in lung diseases and have been identified as attrac-
tive biomarkers due to their accessibility and stability in bodily
fluids (123). Circulating miRNAs are thought to be released from
injured cells, though this is not always the case (124). At the time of
this writing, there have been no studies measuring blood plasma
miRNAs in children with PH. However, several studies have identi-
fied altered levels of miRNAs in buffy coat cells from patients with
Frontiers in Pediatrics | Pediatric Pulmonology February 2014 | Volume 2 | Article 7 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colvin et al. Biomarkers for pediatric pulmonary hypertension
PAH (125), some of which showed good correlation to the disease
severity. Additional studies have identified other miRNAs and, in
animal models, manipulation of mir-204 (126) and mir-21 (127)
showed dramatic therapeutic potential. These studies point to the
urgent need to measure miRNAs in plasma and buffy cot cells
form children with PAH. As has been a common theme through-
out this review, caution must be exercised in the interpretation of
any biomarker measurements in children. In the case of miRNAs,
differential levels may be related to stage of development, gender
differences, etc. Nevertheless, miRNAs may prove to be important
and novel biomarkers in pediatric PAH.
EXHALED BREATH BIOMARKERS
Due its non-invasive nature, breath analysis has the potential
to be a simple and convenient alternative to traditional bio-
markers sources such as blood. Over 40 years ago, Linus Pauling
used gas chromatography to identify volatile organic compounds
(VOCs) in exhaled breath (128). The use of breath biomarkers
has been standardized by law enforcement to measure ethanol
consumption in automobile drivers. Exhaled breath consists of
~500 mL of air, of which the first 150 mL does not participate
in gas exchange (129). To detect VOC at the parts per million
(or lower) level within the nitrogen, oxygen, carbon dioxide,
water, and inert gas mixture, careful separation and identifica-
tion is critical. VOC can derive from both exogenous sources
(ex: pollutants) and endogenous biochemical processes. Here, we
restrict our discussion of exhaled breath biomarkers to nitric oxide
and VOC.
Nitric oxide
Nitric oxide (NO) is produced from the conversion of l-arginine
to l-citrulline by a variety of lung resident cells as a result of the
action of nitric oxide synthases (NOSs) (130). NO acts as a potent
vasodilator but also inhibits vascular smooth muscle cell prolif-
eration. Importantly, inhaled NO therapy is approved by the US
Food and Drug Administration and European Medicine Evalu-
ation Agency for the treatment of infants with persistent PH of
the newborn who have acute hypoxemic respiratory failure (131).
Clinically, the most extensively studied exhaled breath biomarker
is fractional exhaled nitric oxide (FENO) (132). Despite techni-
cal problems with standardization of its measurement, FENO is
lower in patients with PH but rises in responders to therapy.
Thus, serial FENO measurement may be useful. The measure-
ment of NO may be complicated by genetic predisposition. In
a study of Aymaran children (Aymara are an indigenous native
nation who live in the Andes and Altiplano regions of South
America), exhaled NO was actually lower (133). Thus, children
who are protected from hypoxic PH due to high altitude do
not apparently require increased respiratory NO synthesis. This
may be due to NO biosynthesis by endothelium NOS3, by airway
epithelium via NOS2, and/or by non-adrenergic non-cholinergic
nerves via NOS1 (134). NO deficiency is a major therapeutic
target in PH, primarily by stabilization of 3′,5′-cyclic guanosine
monophosphate (cGMP) (phosphodiesterase type 5 inhibition)
(135), and indirectly by prostacyclins and endothelin receptor
antagonists (136). Indeed, a distinct class of emerging therapies
for PH is based upon the antagonistic actions of asymmetric
dimethylarginine (ADMA) regulating NO production (137). Ele-
vated plasma ADMA has been shown to correlate to severity of
idiopathic (138) and chronic thromboembolic PH in adults (139),
and in children with congenital heart disease (140) and sickle cell
disease with PH (141). Moreover, in one study of systemic heart
failure associated with pulmonary venous hypertension, exhaled
NO levels were in higher in hypertensives, but NO did not cor-
relate to increased plasma ADMA (142). Therefore, plasma levels
of the NO-ADMA axis may not be congruent with exhaled NO
measures, making conclusions about biomarker utility somewhat
murky. Despite the complexities of NO biology in the setting of
PH, serial measurement of exhaled NO will likely continue to be
a biomarker, particularly as a measure of response to a variety of
therapies to treat PH.
Volatile organic compound. Recently, a mass spectrometry
approach was used to identify several VOC that could distin-
guish PH patients from controls (143). In that study, exhaled
ammonia was increased in PH patients and correlated with
disease severity. Other studies have also demonstrated differ-
ences in endothelin-1, 6-keto PGF(1alpha), and NT-proBNP in
exhaled breath condensates in individuals with PH compared to
controls (144).
There has been a robust increase in the number of studies uti-
lizing breath analysis in the past decade (“robust” as assessed by
retrieval of 1301 articles in a January 2014 PubMed search for
“exhaled biomarker,” 1042 published from 2003 to 2014, with only
258 publications involving children). Several aspects of exhaled
breath analysis in the clinical setting make it particularly attrac-
tive to apply to the pediatric patient population. Breath tests are
non-invasive and, in many cases, highly repeatable. Children are
quite amenable to breathing treatments when fitted with fun masks
and when clinicians make it fun. The same approaches could be
potentially used to diagnose pediatric PAH and to monitor its
progression and/or response to therapy.
URINARY BIOMARKERS
Besides peripheral blood, additional biological fluids are avail-
able that could offer prognostic value in pediatric PAH. Recently,
Cracowski et al. prospectively studied serum biomarkers and uri-
nary F2-isoprostane in 110 adults with PAH (145). Only urinary
F2-isoprostane is independently associated with an increased 3-
year hazard of death. Furthermore, urinary F2-isoprostane levels
can be elevated in asymptomatic individuals predisposed to PAH,
suggesting that their measurement may herald early stages of the
disease. The source of F2-isoprostanes is unknown, as is their
relevance to pulmonary vascular remodeling and increased PA
pressure. Known to have pro-inflammatory properties and direct
effects on both smooth muscle cells and ECs, they are generally
considered markers of oxidative stress. Urinary F2-isoprostane
levels could be measured in children at diagnosis of PH, and/or
in children of families with histories of familial PAH who may
be asymptomatic. Urinary cGMP levels were found to be higher
in patients with PAH compared to asthma patients and con-
trols (146). Urinary cGMP levels inversely correlated with cardiac
index, likely a reflection of NO and BNP-related hemodynamic
impairment.
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SPECIFIC RECOMMENDATIONS TO APPLY ADULT
PULMONARY HYPERTENSION BIOMARKERS TO CHILDREN
Biomarkers have the potential to be utilized as tools for identifica-
tion of disease phenotype, patient response to therapy, and disease
pathophysiology. Currently, the roles of several biomarkers have
been identified in the pathophysiology of adult PAH, yet further
characterization of these markers needs to be validated, clinical
methods standardized, and engineering refined for development
of robust assays. This level of investigation is not mirrored in
pediatric PAH. A very limited number of studies have been con-
ducted on elucidating biomarkers in children with PAH. It cannot
be overstated that biomarkers in children with PAH are likely to
be even more differentially influenced by additional factors com-
pared with adults with PAH. Such factors include, but are not
limited to: degree of physical activity, age in years and/or stage
of development, gender differences, and nutritional status. Cur-
rently, several hurdles need to be overcome before we can advance
to earlier diagnosis, more accurate prognostication, and improved
therapy in children with PAH. With the exception of PAH associ-
ated with congenital abnormality, the diagnosis of PH in children
is usually delayed, as it is in adults. Therefore, the most power-
ful biomarkers would be those that would identify individuals for
whom the development of PAH is imminent or who are asympto-
matic. Second, we need more sensitive and accurate biomarkers of
disease progression that take into account developmental changes.
Finally,we need biomarkers to identify which children will respond
more favorably to one therapy or combinations of therapies and
to confirm efficacy. For example, as imaging becomes faster, more
powerful, and more precise, we anticipate that it will play an
increasingly important role as a biomarker tool. The use of multi-
ple biomarker panels assessed in large multi-center collaborations
to increase cohort sizes will change the current paradigm of 100s
of studies on a few kids to a few studies on 100s of kids. We recently
summarized the current approach and diagnostic classification of
PAH in children, as based on discussions and recommendations
from the Pediatric Task Force of the fifth World Symposium on
Pulmonary Hypertension (WSPH) in Nice, France (147). We out-
line our perspective on the use of biomarkers with regard to the
classification, etiology, epidemiology and survival, diagnosis, treat-
ment goals, and treatment of pediatric PH. In future discussions,
we hope to reach agreement on the widespread adoption of spe-
cific sets of biomarkers discussed in this review, with a particular
focus on those already identified as informative in adults with PH.
We speculate that such a paradigm shift in experimental approach
will translate into a transformative understanding of the natural
history of PH in children.
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